Related Experiment Video
Updated: Apr 11, 2026
Author Spotlight: Assessing Ischemic Stroke Damage Through Middle Cerebral Artery Occlusion Model
Published on: August 11, 2023
Soluble CD40L Is a Useful Marker to Predict Future Strokes in Patients With Minor Stroke and Transient Ischemic
Jiejie Li1, Yilong Wang1, Jinxi Lin1
1From the Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (J.L., Yilong Wang, J.L., A.W., X.Z., L.L., C.W., Yongjun Wang); China National Clinical Research Center for Neurological Diseases, Beijing, China (Yongjun Wang); Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China (Yongjun Wang); Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China (Yongjun Wang); and Illinois Neurological, Institute Stroke Network, Sisters of the Third Order of St. Francis Healthcare System, University of Illinois College of Medicine, Peoria (D.W.).
Background And Purpose:
Elevated soluble CD40 ligand (sCD40L) was shown to be related to cardiovascular events, but the role of sCD40L in predicting recurrent stroke remains unclear.
Methods:
Baseline sCD40L levels were measured in 3044 consecutive patients with acute minor stroke and transient ischemic attack, who had previously been enrolled in the Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events (CHANCE) trial. Cox proportional-hazards model was used to assess the association of sCD40L with recurrent stroke.
Results:
Patients in the top tertile of sCD40L levels had increased risk of recurrent stroke comparing with those in the bottom tertile, after adjusted for conventional confounding factors (hazard ratio, 1.49; 95% confidence interval, 1.11-2.00; P=0.008). The patients with elevated levels of both sCD40L and high-sensitive C-reactive protein also had increased risk of recurrent stroke (hazard ratio, 1.81; 95% confidence interval, 1.23-2.68; P=0.003).
Conclusions:
Elevated sCD40L levels independently predict recurrent stroke in patients with minor stroke and transient ischemic attack.
Clinical Trial Registration:
URL: http://www.clinicaltrials.gov. Unique identifier: NCT00979589.
More Related Videos
08:22Isolation and Flow Cytometric Assessment of Neuroimmune Interactions in a Mini-Stroke Murine Model
Published on: June 20, 2025
09:48Quantification of Neurovascular Protection Following Repetitive Hypoxic Preconditioning and Transient Middle Cerebral Artery Occlusion in Mice
Published on: May 4, 2015